We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$240M 11.01%
1,804,703
+410,684
+29% +$46.5M
PTGX icon
2
Protagonist Therapeutics
PTGX
$9.34B
$118M 5.39%
960,863
-33,256
-3% -$3.47M
ROIV icon
3
Roivant Sciences
ROIV
$25.1B
$112M 5.11%
3,157,008
-128,898
-4% -$3.81M
SPY icon
4
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$96.4M 4.41%
129,087
+53,147
+70% +$38.5M
IMVT icon
5
Immunovant
IMVT
$8.51B
$89.8M 4.11%
2,330,716
-348,294
-13% -$10.6M
ZLAB icon
6
Zai Lab
ZLAB
$2.93B
$64M 2.93%
3,369,034
+1,943,667
+136% +$38.4M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.99B
$47.8M 2.19%
1,288,053
+1,147,381
+816% +$34.8M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$9B
$45.7M 2.09%
1,222,080
+82,749
+7% +$3.08M
BOXX icon
9
Alpha Architect 1-3 Month Box ETF
BOXX
$14.3B
$39.5M 1.81%
337,125
– –
CYTK icon
10
Cytokinetics
CYTK
$10B
$39M 1.79%
457,907
-174,649
-28% -$12.5M
SEPN
11
Septerna Inc
SEPN
$1.82B
$31.5M 1.44%
940,747
-149,071
-14% -$4.23M
AVR
12
Anteris Technologies
AVR
$852M
$31M 1.42%
3,145,096
-644,036
-17% -$4.9M
EDIT icon
13
Editas Medicine
EDIT
$485M
$28.8M 1.32%
+8,889,000
New +$26M
DNLI icon
14
Denali Therapeutics
DNLI
$3.84B
$26.5M 1.21%
1,029,080
-842,375
-45% -$17.3M
SYRE icon
15
Spyre Therapeutics
SYRE
$7.97B
$25.2M 1.15%
283,982
-54,341
-16% -$3.97M
VIR icon
16
Vir Biotechnology
VIR
$1.83B
$25M 1.15%
2,456,677
-288,037
-10% -$2.74M
PRAX icon
17
Praxis Precision Medicines
PRAX
$9.63B
$24.9M 1.14%
74,253
+72,753
+4,850% +$23M
INSM icon
18
Insmed
INSM
$25.9B
$24.4M 1.12%
228,520
+193,128
+546% +$23.4M
CLDX icon
19
Celldex Therapeutics
CLDX
$3.07B
$23.1M 1.06%
619,542
+191,726
+45% +$6.19M
VKTX icon
20
Viking Therapeutics
VKTX
$3.75B
$22.4M 1.02%
574,038
+346,321
+152% +$11.2M
TSHA icon
21
Taysha Gene Therapies
TSHA
$1.88B
$20.7M 0.95%
3,040,466
+61,037
+2% +$361K
MNPR icon
22
Monopar Therapeutics
MNPR
$751M
$20.1M 0.92%
217,595
-46,683
-18% -$2.89M
OVID icon
23
Ovid Therapeutics
OVID
$547M
$20M 0.91%
7,417,479
+2,873,366
+63% +$7.41M
ELVN icon
24
Enliven Therapeutics
ELVN
$4.24B
$19.7M 0.9%
387,718
+58,178
+18% +$2.47M
ENTA icon
25
Enanta Pharmaceuticals
ENTA
$396M
$19.6M 0.9%
1,344,510
+1,293,153
+2,518% +$17.4M
1
2 3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.